

Ontario Public Drug Programs

Drug Submission Status

Report for September 2016

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Rizatriptan	Maxalt	rizatriptan benzoate	10mg	Tablet	02441144
Mantra Pharma Inc	M-Sildenafil	Viagra	sildenafil citrate	100mg	FC tablet	02430037
Sanis Health Inc.	Sildenafil	Viagra	sildenafil citrate	50mg	FC tablet	02406152
Sanis Health Inc.	Sildenafil	Viagra	sildenafil citrate	100mg	FC tablet	02406160
Teva Canada Limited	Teva-Tadalafil	Cialis	tadalafil	2.5mg	FC tablet	02440148

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Teva Canada Limited	Teva-Tadalafil	Cialis	tadalafil	5mg	FC tablet	02440156
Teva Canada Limited	Teva-Tadalafil	Cialis	tadalafil	10mg	FC tablet	02440164
Teva Canada Limited	Teva-Tadalafil	Cialis	tadalafil	20mg	FC tablet	02440172